Trials / Completed
CompletedNCT05568706
A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of EDP-938 in Non-hospitalized Adults With Acute Respiratory Syncytial Virus Infection Who Are at High Risk for Complications
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 186 (actual)
- Sponsor
- Enanta Pharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult subjects with confirmed RSV infection who are at high risk for complications after RSV infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EDP-938 | Subjects will take EDP-938 once daily for 5 days |
| DRUG | Placebo | Subjects will take matching placebo, once daily for 5 days |
Timeline
- Start date
- 2022-11-29
- Primary completion
- 2025-06-23
- Completion
- 2025-06-23
- First posted
- 2022-10-06
- Last updated
- 2025-07-01
Locations
84 sites across 12 countries: United States, Argentina, Bulgaria, Colombia, Czechia, Malaysia, Mexico, Poland, Slovakia, South Africa, Spain, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05568706. Inclusion in this directory is not an endorsement.